Literature DB >> 20001109

MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats.

Wen-Fu Wang1, Shey-Lin Wu, Ying-Ming Liou, An-Li Wang, Cornelius Rainer Pawlak, Ying-Jui Ho.   

Abstract

Animal models of Parkinson's disease with dementia would greatly facilitate research into the underlying causes of this disorder. Here, we showed that bilateral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into the substantia nigra pars compacta (SNc) of Wistar rats caused degeneration of nigrostriatal dopaminergic neurons, cell loss in the hippocampal CA1 area, as well as microglial activation and increase of interleukin-2 levels in several brain regions. In addition, increase of anxiety-like behavior and impairment of object recognition were observed in the MPTP-lesioned rats. These findings suggest that neuroinflammation may contribute to MPTP-induced neurodegeneration and behavioral deficits, which is suggested as an animal model of Parkinson's disease dementia.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20001109     DOI： 10.1037/a0017401

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN： 0735-7044            Impact factor:   1.912


  16 in total

1.  MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex.

Authors:  Giulia Costa; Nicola Simola; Micaela Morelli
Journal:  Psychopharmacology (Berl)       Date:  2014-04-01       Impact factor: 4.530

2.  Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats.

Authors:  Naiani F Marques; Adalberto A Castro; Gianni Mancini; Fernanda L Rocha; Adair R S Santos; Rui D Prediger; Andreza Fabro De Bem; Carla I Tasca
Journal:  Neurotox Res       Date:  2017-11-21       Impact factor: 3.911

3.  Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.

Authors:  Danúbia Bonfanti Santos; Dirleise Colle; Eduardo Luiz Gasnhar Moreira; Mariana Appel Hort; Marcelo Godoi; Gael Le Douaron; Antonio Luiz Braga; Jamil Assreuy; Patrick Pierre Michel; Rui Daniel Prediger; Rita Raisman-Vozari; Marcelo Farina
Journal:  Mol Neurobiol       Date:  2016-02-06       Impact factor: 5.590

4.  Parallel declines in cognition, motivation, and locomotion in aging mice: association with immune gene upregulation in the medial prefrontal cortex.

Authors:  Kelly A Bordner; Robert R Kitchen; Becky Carlyle; Elizabeth D George; Milind C Mahajan; Shrikant M Mane; Jane R Taylor; Arthur A Simen
Journal:  Exp Gerontol       Date:  2011-03-29       Impact factor: 4.032

5.  Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia.

Authors:  Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Travis R Stoub; Christopher G Goetz; Leyla deToledo-Morrell
Journal:  Mov Disord       Date:  2012-03-12       Impact factor: 10.338

6.  Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats.

Authors:  Jin-Song Yang; Xiao-Hong Wu; Hao-Gang Yu; Li-Song Teng
Journal:  Inflammopharmacology       Date:  2017-06-02       Impact factor: 4.473

7.  Cognitive dysfunction with aging and the role of inflammation.

Authors:  Arthur A Simen; Kelly A Bordner; Mark P Martin; Lawrence A Moy; Lisa C Barry
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

8.  CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.

Authors:  Fabrine Sales Massafera Tristão; Márcio Lazzarini; Sabine Martin; Majid Amar; Walter Stühmer; Frank Kirchhoff; Lucas Araújo Caldi Gomes; Laurance Lanfumey; Rui D Prediger; Julia E Sepulveda; Elaine A Del-Bel; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2015-09-24       Impact factor: 3.911

9.  Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease.

Authors:  Fabrine S M Tristão; Majid Amar; Ines Latrous; Elaine A Del-Bel; Rui D Prediger; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-05-21       Impact factor: 3.911

10.  Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease.

Authors:  Anamitra Ghosh; Monica R Langley; Dilshan S Harischandra; Matthew L Neal; Huajun Jin; Vellareddy Anantharam; Joy Joseph; Timothy Brenza; Balaji Narasimhan; Arthi Kanthasamy; Balaraman Kalyanaraman; Anumantha G Kanthasamy
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-02       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.